Adoram is a UNIGE spinoff that is developing next-generation allosteric small molecule drugs targeting A2A receptors for cancer and inflammatory diseases, powered by a proprietary AI-enhanced GPCR discovery platform and in-house screening technologies for rapid, high-quality lead generation.
Products, services, technology
Adoram develops two A2A receptor allosteric small molecule assets: a best-in-class NAM for solid tumor immunotherapy, and a first-in-class PAM for inflammatory and metabolic diseases with tissue-selective, cytokine-lowering activity
Cooperation possibilities
Adoram offers flexible cooperation options, including co-creation of IP on any Gs or Gi-linked GPCR target, collaborative use of its AI-enhanced allosteric discovery platform, and out-licensing or sale of individual A2AR assets to pharma or biotech partners.
- https://adoram.ch
- Send an email
- David Pejoski
Some insights
Allosteric modulation unlocks various advantages compared to conventional small molecule therapies, translating to benefits to patients like improved therapeutic index, reduced off target effects, and more powerful disease reversal.
The discoveries made at the University of Geneva that Adoram is developing have been patented successfully in several geographies, published as the first negative allosteric modulators of A2AR, and described as a 'new weapon against cancer' by experts in the field.
The entire ecosystem plays a role in sustaining a high level of innovation in Switzerland. Professors with outstanding technical solutions, entrepreneurs who succeed during challenging times, and senior pharma experts with a track record of bringing new treatments all the way through the clinic.
Our core strength is the ability to identify allosteric modulators (chemistry/biology). Closer to the clinic we'd like to integrate more regulatory and clinical experts, as well as bring expert deal makers to the table during investment, licensing, and acquisition scenarios.
Promote events that facilitate startups being matched with appropriate investors, including VCs, but also alternative investors such as family offices or HNWI, whom are difficult to identify and connect with.
1. Swiss and broader European/UK VCs, as well as family offices, that are interested in direct biotech investments.
2. Pharma, but especially mid-sized biotech companies, that are looking to in-license *preclinical* assets
